Background
We aimed to investigate (a) the long‐term survival of corneal grafts from α1,3‐galactosyltransferase gene‐knockout miniature (GTKOm) pigs in non‐human primates as a primary outcome and (b) the effect of anti‐CD20 antibody on the survival of corneal grafts from GTKOm pigs as a secondary outcome.
Methods
Nine rhesus macaques undergoing full‐thickness corneal xenotransplantation using GTKOm pigs were systemically administered steroid, basiliximab, intravenous immunoglobulin, and tacrolimus with (CD20 group) or without (control group) anti‐CD20 antibody.
Results
Graft survival was significantly longer (P = .008) in the CD20 group (>375, >187, >187, >83 days) than control group (165, 91, 72, 55, 37 days). When we compared the graft survival time between older (>7‐ month‐old) and younger (≤7‐month‐old) aged donor recipients, there was no significant difference. Activated B cells were lower in the CD20 group than control group (P = .026). Aqueous humor complement C3a was increased in the control group at last examination (P = .043) and was higher than that in the CD20 group (P = .014). Anti‐αGal IgG/M levels were unchanged in both groups. At last examination, anti‐non‐Gal IgG was increased in the control group alone (P = .013).
Conclusions
The GTKOm pig corneal graft achieved long‐term survival when combined with anti‐CD20 antibody treatment. Inhibition of activated B cells and complement is imperative even when using GTKO pig corneas.